Abstract
Prostacyclin, one of the cyclooxygenase metabolites, causes various biological effects, including vasodilation and antithrombogenicity, and is also involved in several pathophysiological effects, such as inflammatory pain and bladder disorders. The prostacyclin receptor (IP receptor) agonists iloprost, cicaprost, and carbacyclin have been useful for clarifying the role of the IP receptor signaling, since the endogenous ligand, prostacyclin, is very unstable. On the other hand, only a few IP receptor antagonists have been reported to date. Here, we characterized the biological activities of 2-[4-(1H-indol-4-yloxymethyl)-benzyloxycarbonylamino]-3-phenyl-propionic acid (compound A) in various in vitro systems. Compound A inhibited the accumulation of the second messenger cyclic AMP in the UMR-108 rat osteosarcoma cell line and primary cultured rat dorsal root ganglion (DRG) neurons in a concentration-dependent manner up to 10 μM, without affecting other eicosanoid receptors. Functionally, the IP receptor plays an important role in DRG neuron sensitization, which is measured by release of the neurotransmitter substance P. Although the effects of iloprost or Lys-bradykinin, an inflammatory peptide, alone on substance P release were limited, stimulation of the neurons with both these ligands induced substantial amounts of substance P release. This synergistic effect was suppressed by compound A. Collectively, these results suggest that compound A is a highly selective IP receptor antagonist that inhibits iloprost-induced sensitization of sensory neurons. Furthermore, these findings suggest that IP receptor antagonist administration may be effective for abnormal neural activities of unmyelinated sensory afferents. Compound A should prove useful for further investigations of the IP receptor in various biological processes.
Footnotes
-
doi:10.1124/jpet.105.091967.
-
ABBREVIATIONS: PG, prostaglandin; CRTH2, chemoattractant receptor homologous molecule expressed on T-helper 2 cells; EP, prostanoid EP receptor; TP, thromboxane A2 receptor; IP, prostacyclin receptor; DRG, dorsal root ganglion; PKA, protein kinase A; compound A, 2-[4-(1H-indol-4-yloxymethyl)-benzyloxycarbonylamino]-3-phenyl-propionic acid (C26H24N2O5); compound B, (R)-2-(4-phenoxymethyl-benzyloxycarbonylamino)-3-phenyl-propionic acid (C24H23NO5); H89, N-[2-(4-bromocinnamylamino)ethyl]-5-isoquinoline; LTB4, leukotriene B4; BSA, bovine serum albumin; CHO, Chinese hamster ovary; BLT1, leukotriene B4 receptor 1; l CAY10441, (4,5-dihydro-1H-imidazol-2-yl)-[4-(4-isopropoxybenzyl)phenyl]amine; VR1, vanilloid receptor 1; SC-51322, 8-chlorodibenz[b,f][1,4]oxazepine-10(11H) carboxylic acid,2-[3-[(2-furanylmethyl)-thio]-1-oxopropyl]hydrazide; U-46619, 9,11-dideoxy-9,11-methanoepoxy-prostaglandin F2; HEL, human erythroleukemia.
- Received July 3, 2005.
- Accepted August 17, 2005.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|